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Abstract  
 
Aim: To examine prospectively over a period of 4 years the profile of cannabis dependence and the 
risk of specific dependence criteria in a community sample of adolescents.  
Methods: A representative community sample of 2446 young adults aged 14–24 years at baseline was 
followed up over a period of 4 years. Frequency of use measures and of criteria for DSM-IV 
dependence were assessed by standardized diagnostic interview measures (CIDI). To explore the 
nature of this association, frequency of use and concomitant use of other psychoactive substances was 
considered.  
Results: 30% of the sample were cannabis users. Among all users 35% met at least one dependence 
criterion. Most frequently reported dependence criteria among all users were withdrawal (17%), 
tolerance (15%), loss of control (14%) and continued use despite a health problem (13%). Even 
without concomitant use of other illicit drugs, 22% of low frequency users and 81% of high frequency 
users met at least one dependence criterion. Symptom patterns were similar in high and low frequency 
users. The occurrence of a dependence syndrome or of specific dependence criteria could not be 
attributed to the use of other illicit drugs or to comorbid nicotine and alcohol dependence.  
Conclusions: Regular cannabis use in adolescence is associated with the development of a dependence 
syndrome. This association cannot be explained by the concomitant use of other illicit substances or 
by comorbid nicotine and alcohol dependence.   
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1. Introduction  
 
Cannabis is the most prevalent illicit substance used in many western countries (American 
Psychiatric Association, 1994) such as the US, Australia, New Zealand and most European 
countries (European Monitoring Centre for Drugs and Drug Addiction (EBDDA), 2003), with 
an estimated lifetime use rate of 20–46% in the general population (Anthony et al., 1994; 
Australian Institute of Health and Welfare, 1999; European Monitoring Centre for Drugs and 
Drug Addiction (EBDDA), 2003) and even higher rates among adolescents and young adults 
(37–69%) (Sydow et al., 2001; Anthony et al., 1994; Coffey et al., 2002; Fergusson and 
Horwood, 2000; Poulton et al., 1997; Young et al., 2002). Some researchers claim that in this 
age group cannabis use can already be regarded a ‘normal’ experience (Fergusson and 
Horwood, 2000). First use typically occurs in early adolescence and peak use in mid- to late 
adolescence and young adulthood (Hall and Solowij, 1998; Sydow et al., 2001; Young et al., 
2002) with some indications that the first use of cannabis has shifted to an earlier age (Dennis 
et al., 2002; Sydow et al., 2001; Degenhardt et al., 2000; Muller and Gmel, 2002).  
 
Fairly consistently across studies it has been estimated that approximately 10% of US 
individuals who ever used cannabis become daily users (Anthony et al., 1994), that younger 
users more probably become daily users (Anthony et al., 1994; Zoccolillo et al., 1999), that 
frequency of use and early onset are associated with increased risk for developing a 
dependence syndrome (Coffey et al., 2003; Hall et al., 1994; Sydow et al., 2002; Poulton et 
al., 1997) and that dependent cannabis use appears to be fairly stable over longer periods of 
time (Swift et al., 2000; Wittchen et al., 1998a).  
 
Lifetime prevalence rates for cannabis dependence in the US have been estimated to be 4% 
(Anthony and Helzer, 1991; Anthony et al., 1994). Higher prevalence rates have been 
reported from samples of adolescents and young adults in the US and New Zealand (5–9%, 
(Anthony et al., 1994; Fergusson and Horwood, 2000; Young et al., 2002). Recent data from 
various EU countries suggest, however, considerably lower rates (subjects up to age 65: 0.6–
1.0%, Wittchen, 2000; de Graaf, 2004; subjects up to the age of 25 years; 1.4–2.3%; Wittchen 
and Jacobi, 2004; Perkonigg et al., 1997).  
 
Except for several studies in highly selective clinical drug users samples (e.g. Winters et al., 
1999; Chung et al., 2003; Crowley et al., 1998) little attention, however, has been paid to the 
symptom profile of cannabis dependence in community samples. Anthony and Trinkoff 
(1989) summarized that daily cannabis users most frequently reported ‘psychological 
problems attributed to drug use’ and ‘need for larger amounts’ (both 21%) as the most 
frequent symptoms: Among non-daily users ‘psychological problems attributed to drug use’ 
was considerably less frequent (10%); ‘social problems attributed to drug use’ was the next 
most frequently reported item (4%). Swift et al. (2001) presented rates of 12-month DSM-IV 
cannabis dependence criteria from the Australian adult population: ‘persistent 
desire/unsuccessful efforts to control use’ (37%) and ‘withdrawal/withdrawal relief’ (30%) 
were the most frequent criteria among cannabis users. Among dependent users the frequency 
of these criteria was much higher (87% ‘desire to control use’ and 89% ‘withdrawal’) as 
compared to non-dependent cannabis users (23% ‘desire to control use’ and 14% 
‘withdrawal’). Coffey et al. (2002) reported for a sample of the 20–21 year old Australians 
‘persistent desire to control use’ as the most frequent 12-month criterion in cannabis users 
(10%), followed by ‘unintentional use’ (8%). Young et al. (2002) interviewed 12–18 year old 
adolescents in the USA. In their sample, ‘continued use despite physical or psychological 
problems’ (42% of the boys and 48% of the girls) and ‘tolerance’ (36% of the boys and 33% 
of the girls) were the most frequent. Dennis et al. (2002) reported as the most frequent 12-
month DSM-IV cannabis dependence criteria across all age groups (a) ‘spending a great deal 
of time getting, using or getting over effects of cannabis’ (54% of the 12–17 years old users, 
49% of the 18–25 years old users, 32% of the over 25 years old users, 42% of all users) and 
(b) ‘tolerance’ (39% of the 18–25 years old users, 26% of the over 25 years old users, 33% of 
all cannabis users); in the youngest age group, however, ‘used cannabis more often or in 
larger amounts than intended’ was found to be the second most frequently mentioned 
symptom (48%).  
 
To summarize, the available studies of symptoms of dependence among cannabis users 
indicate some variability in findings. Part of this variation seems to be related to frequency of 
use and design effects, such as age composition of the studied sample. Further it is 
noteworthy, that the available epidemiological studies have not yet demonstrated that 
dependence symptoms and withdrawal as the core symptom can be directly related to the use 
of cannabis, respectively, the frequency and duration of use. An alternative explanation for 
the existence of dependence symptoms among cannabis users could be that the emergence of 
such symptoms is due to the concomitant use of other drugs, such as nicotine, alcohol or other 
psychoactive substances. This alternative hypothesis and explanation remains poorly studied 
as well.  
 
2. Aims  
 
To examine the symptom profile of cannabis dependence prospectively in a large community 
sample of adolescents and young adults and to examine the following questions:  
 
1. How frequent are DSM-IV dependence symptoms among low frequency (LFU) and high 
frequency (HFU) cannabis users?  
2. Which dependence symptoms are specific for users meeting DSM-IV criteria for cannabis 
dependence?  
3. To what degree are dependence symptoms in cannabis users attributable to the concomitant 
use of other illicit and licit (alcohol and nicotine) drugs?  
 
3. Method  
 
The Early Developmental Stages of Psychopathology Study explores the prevalence, 
incidence, comorbidity, risk factors, protective factors and 4-year course of mental disorders, 
with specific emphasis on substance-use disorders in a representative general population 
sample (Lieb et al., 2000; Wittchen et al., 1998a,d; Perkonigg et al., 1997, 1999; Sydow et al., 
2001, 2002). The study is based on three waves, the first conducted in 1995 (t0), the second in 
1996–1997 (t1: only the younger cohort was assessed), and the third in 1998–1999 (t2: again 
with the total sample).  
 
3.1. Baseline sample and follow-up investigations  
 
The sample was randomly drawn from the 1994 government registries of residents in 
metropolitan Munich. A total of 3021 participants aged 14–24 years (birth cohorts 1970–
1981) were successfully interviewed at baseline, resulting in a response rate of 71%. Since the 
study was designed with a special interest in early stages of substance use disorders, 14–15 
year olds were sampled at twice the probability of 16–21 year olds, and 22–24 year olds were 
sampled at half the probability. For youth under 18 years parents gave their signed permission 
to participate in the study. At baseline, almost three-quarters of the participants were students, 
36% at the secondary level and 26% at the university level, and 20% of the participants were 
employed. 62% were living with their parents, 23% alone, and 12% with their 
partners/spouses. The majority of the respondents (59%) were classified as middle class, 
reflecting the population of Munich. To account for different sampling probabilities for the 
different age groups, as well as for noncontact and non-response, the data were adjusted by 
age, sex and geographic location at baseline, in order to match the distribution of the original 
sampling frame. Detailed descriptions of the sampling procedures of the baseline 
investigation and reasons for non-response have already been presented elsewhere (Wittchen 
et al., 1998c,d).  
 
The follow-up investigations covered an overall period of 42 months (range: 34–50 months). 
As emphasis was laid on early stages of substance abuse patterns, the first follow-up (t1; 
conducted in 1996/1997) was confined to the younger sub-sample (aged 14–17 years at 
baseline), with a response rate of 88% (N = 1228). The second follow-up (t2) included all 
baseline respondents and was conducted in 1998–1999; the response rate was 84% (N = 
2548). Of these, 102 participants did not want to respond to questions about illicit drug use at 
either t0, t1 or t2. In order to use data from all three assessments in this paper, the analysis are 
based on the results of N = 2446 subjects with complete information at second follow-up: 
1101 participants in the younger cohort (aged 14–17 years at baseline, born between 1977 and 
1981), and 1345 in the older cohort (aged 18–24 years at baseline, born between 1970 and 
1977). Noteworthy changes in socio-demographic characteristics from baseline to second 
follow-up were found only for school/employment status (t2: secondary school: 13%, 
employed: 36%) and living arrangements (t2: with parents: 40%; with partner: 23%). There 
was no selective attrition due to age, gender or geographic distribution. A significantly high 
rate of drop-outs between t0 and t2 was observed among subjects with nicotine dependence 
(OR: 1.6; 95% CI: 1.2–2.0), dysthymia (OR: 2.7; 95% CI: 1.6–4.4) and anorexia nervosa 
(OR: 3.7; 95% CI: 1.3–10.4).  
 
3.2. Diagnostic assessment  
 
Face-to-face computer-assisted interviews were administered by clinical psychologists at 
baseline and at the two follow-ups. Diagnostic assessments (t0–t1– t2) were based on the 
Munich version of the Composite International Diagnostic Interview (M-CIDI, Wittchen and 
Pfister, 1997). At baseline, lifetime and past 12 month substance use, substance use disorders 
and other mental disorders were assessed according to DSM-IV criteria. In both follow-up 
investigations, substance use and diagnoses during the follow-up periods and for the previous 
12 months were evaluated. The M-CIDI is an updated version of the World Health 
Organization s CIDI version 1.2 (WHO-CIDI; World Health Organization, 1992), which 
incorporates questions to cover DSM-IV (American Psychiatric Association, 1994) and ICD-
10 (World Health Organization, 1990) diagnostic criteria. The reliability and procedural 
validity of the M-CIDI has been established (Wittchen, 1994; Wittchen et al., 1998b; Lachner 
et al., 1998; Reed et al., 1998).  
 
The assessment of illicit drug use, abuse and dependence has been comprehensively described 
elsewhere (Perkonigg et al., 1998). With regard to cannabis withdrawal, the M-CIDI assesses 
withdrawal symptoms for cannabis in the same way as for all other illegal substances. 
Participants were presented a list of 27 symptoms, among those craving, irritability, anxiety, 
sleep difficulty, abdominal cramping and others, and asked if they experienced any of these 
symptoms due to their cannabis use. In case of an affirmative answer they were asked if they 
had used the substance in order to avoid such symptoms.  
 
3.3. Data analysis  
 
Lifetime prevalence at baseline denotes the weighted rate of occurrence of any pattern of use 
or a specific diagnostic criterion in the total sample or in the subsamples. It covers the 
respondents’ lifetime period prior to the assessment at baseline. Cumulative lifetime incidence 
was calculated by adding baseline, t1 and t2 follow- up incident cases (new outcomes during 
the follow-up period (t0 to t2) among non-cases at baseline). In line with the WHO-CIDI 
conventions (World Health Organization, 1990; Lachner et al., 1998), four mutually exclusive 
patterns of drug use were considered (never; 1 time; 2–4 times; 5 times and more). The 
question about use of drugs five times and more in lifetime is used within the M-CIDI as a 
gateway question to exclude purely experimental users.  
 
Only for the individuals that used cannabis at least 5 times in their life the M-CIDI examines 
in detail (a) cannabis use frequency in the period (by year) in which the substance was used 
most frequently (peak time use: almost every day, 3–4 days per week, 1–2 days per week, 1–3 
days per month, less than once a month) and (b) DSM-IV dependence criteria. Summarized 
use frequency categories are reported (monthly: 63 days per month, weekly: 1–2 days per 
week, daily: P3 days per week), choosing the latter cut-off because the “Risk of dependence 
among those using 3–4 days/week […] was closer to that among daily users than among less 
frequent users” (Coffey et al., 2002). For subsequent analyses, the categories were merged 
into those with low frequency use (LFU), defined as participants who never consumed over 
two days in one week (monthly and weekly use), and high frequency use (HFU), defined as 
participants who consumed at least three days in one week in the peak cannabis use period 
(daily use).  
 
For other illicit substances use was defined as cumulative use of any psychoactive drug other 
than cannabis, tobacco, alcohol or caffeine on five or more occasions in life (‘concomitant use 
of other illicit drugs’). Analysis of the associations between illicit drug use and specific 
dependence criteria were also controlled for licit drug (alcohol and nicotine) dependence.  
 
To account for design effects introduced by the use of weighted data, confidence intervals 
were estimated using the software package STATA (Stata Corporation, 2003) that applies the 
Huber-White sandwich matrix in this case (Royall, 1986). Cumulative lifetime incidence rates 
and logistic regressions are reported for cannabis use and specific dependence criteria, 
considering concomitant use of other illicit drugs as defined above. As development of 
substance dependence is known to be related to age and gender, all regressions were 
controlled for these two variables to approach a randomized distribution of age and gender in 
the studied sub-groups. If not indicated otherwise, differences between groups are based on 
comparisons of confidence intervals.  
 
4. Results  
 
4.1. Lifetime prevalence of cannabis use by concomitant drug use status  
 
Table 1 presents the baseline lifetime prevalence of cannabis use frequency for the total 
sample and for two mutually exclusive subgroups of respondents with and without 
concomitant use of other illicit drugs. As shown in Table 1 at baseline one third (34.2%) of 
the total sample used or had used cannabis. 16% were regular users, defined as use more than 
5 times, 4.7% were daily users. At baseline the vast majority of cannabis users in the sample 
did not report the use of other illicit drugs. However, subjects with concomitant illicit drug 
use reveal considerably higher proportions of daily consumption (2.2%/4.5% = 48.9%) as 
compared to users without concomitant use (2.6%/29.6% = 8.8%).  
 
4.2. Cumulative incidence of cannabis use in the follow-up period by concomitant drug use 
status  
 
At follow-up t2 a considerable increase of regular cannabis users can be noted (Table 2). The 
cumulative lifetime incidence for any cannabis use and for regular (5+) use is 46.8% and 
29.9%, respectively. The increases apply to both users with and without concomitant use of 
other illicit drugs. The total number of concomitant drug users in the sample had doubled. 
Table 2 also indicates considerably higher proportions of daily cannabis users in those with 
concomitant illicit drug use (3.9%/ 9.0% = 43.3%) as compared to those without (2.9%/ 
37.8% = 7.7%).  
 
In summary, concomitant use of other illicit drugs is linked to a higher cannabis use 
frequency. To account for the confounding effect of cannabis use frequency on the following 
analyses of concomitant drug use and cannabis dependence criteria, the following analyses 
were carried out separately for low (LFU) and high (HFU) frequency cannabis users.  
 
4.3. Cumulative incidence of cannabis dependence symptoms by concomitant drug use among 
lifetime cannabis users  
 
One third of all cannabis users met at least one DSMIV dependence criterion in their lifetime, 
16.7% only one, 6.6% two and 11.2% three or more (Table 3). The most frequently reported 
symptoms were: withdrawal, tolerance, consumed more of the substance than intended (‘loss 
of control’) and continued to take cannabis despite a health problem probably caused by the 
drug. Psychological problems played a more important role for the last criterion than physical 
problems.  
 
The table also informs about the frequency of dependence symptoms by cannabis use 
frequency and concomitant use of other illicit drugs. Fairly irrespective of concomitant illicit 
drug use, LFU subjects (N = 566) had overall a low probability of experiencing any, as well 
as two or three dependence criteria. Most frequent were withdrawal, loss of control, use 
despite a health problem and tolerance.  
 
A considerably higher probability of dependence criteria resulted for HFU subjects. In 
addition, HFUs revealed some differences in the respective symptom pattern of those with 
and without concomitant illegal drug use: Concomitant drug users more often experienced 
psychological problems due to cannabis, and endorsed ‘use despite health problems’ more 
frequently. Next frequent criteria were withdrawal and tolerance. In contrast to LFUs, time 
excess obtaining/recovering played a major role and was one of the most frequent criteria in 
HFU subjects.  
 
4.4. Dependence symptoms among those with full-threshold cannabis dependence  
 
Subjects with a diagnosis of DSM-IV cannabis dependence most frequently reported the 
following specific 12-month dependence criteria: withdrawal (90.6%), tolerance (83.0%), 
continued use despite a health problem (72.2%) and time excess obtaining/recovering 
(65.1%). Thus, subjects fulfilling a diagnosis of cannabis dependence reported a similar 
pattern of dependence criteria as reported for HFUs in Table 3.  
 
There were several noteworthy differences in the patterns of dependence symptoms between 
dependent subjects with and without concomitant drug use.1 These differences were 
associated with a considerably higher total number of criteria met by the concomitant use 
group. To check for differences of means, the number of criteria were transformed with a 
Box–Cox-transformation to approximate a normal curve of distribution (Chen, 1995). A linear 
regression controlled for sex and age estimated the association between concomitant use and 
the number of criteria. A significant difference was found between the two groups regarding 
the mean of criteria met (Wald F (1, 52) = 0.741, p = 0.040). Among persons with a full-
threshold cannabis dependence those with concomitant drug use met more lifetime cannabis 
dependence criteria than those without concomitant use (on the original scale: mean without: 
4.2, SD: 1.3; mean with: 4.9, SD: 1.2).   
 
4.5. Degree of dependence symptoms in cannabis users attributable to the concomitant use of 
other drugs  
 
For LFU subjects no association between concomitant use and dependence criteria was found. 
HFU concomitant users were at a higher risk to continue their cannabis use despite a health 
problem compared to pure cannabis users. This higher risk was attributable to ‘use despite a 
psychological problem’ in particular, because concomitant use was associated with the 
existence of a psychological problem due to cannabis. Concomitant HFUs had a lower risk to 
perceive loss of control over their cannabis use than HFUs without concomitant illegal drug 
use. Neither in LFUs nor in HFUs concomitant use of illicit substances was associated with 
the development of a certain number of dependence criteria or a full-blown dependence 
syndrome.  
 
To examine whether the increased risk of cannabis dependence symptoms might be due to the 
existence of a dependence syndrome of nicotine or alcohol, the logistic model presented in 
Table 4 was rerun by controlling for nicotine or alcohol dependence. The associations and 
confidence intervals remained unchanged, and the significant odds ratios changed from 0.4 to 
0.3 (‘loss of control’ in HFUs) and from 3.1 to 2.6 (‘use despite health problem’ in HFUs). 
This suggests that licit substance dependence does not affect the risk of cannabis dependence 
symptoms.  
 
5. Discussion  
 
The core findings of this paper are: first, a substantial proportion of young cannabis users 
develop DSM-IV dependence symptoms fairly independently of their use of other illicit 
substances as well as independently of nicotine dependence and alcohol dependence. Second, 
both, the risk of symptoms as well as the syndrome of dependence appear to be “dose-
dependent”, occurring mainly in high frequency users as defined in this study.  
 
To our knowledge this is the first epidemiological study among adolescents and young adults 
sampled in the community to examine and compare dependence symptoms in cannabis users 
with and without concomitant use of other illicit drugs. Compared to previous findings in 
clinical samples, such community samples are assumed to be less affected by biases such as 
helpseeking behavior, severity and demoralization, and thus can be expected to be of higher 
ecological validity. A further strength of the study is its longitudinal nature during the peak 
risk period of adolescence/young adulthood, possibly enhancing the value of findings for 
prevention and intervention.  
 
Some limitations should be noted before discussing these findings: First, some attrition 
occurred from baseline to follow-up that might have had an effect on the data. A significantly 
high rate of drop-outs between t0 and t2 was observed among nicotine dependents. 
Additionally, 102 participants of the study did not want to answer to questions about illicit 
drug use at one or more of the assessments. This potential selective attrition, particularly in 
relation to nicotine, might have resulted in the description of a more favorable pattern of 
cannabis use and dependence. Second, diagnoses at baseline were retrospective and, therefore, 
subject to possible recall problems or biases, which might be accentuated by potential adverse 
effects of cannabis on memory performance. Finally, it must be highlighted that the validity 
of specific DSM-IV dependence criteria in general and that of specific CIDI items in 
particular, is still controversially discussed (e.g., Torrens et al., 2004; Cottler et al., 1997; 
Hasin et al., 1997; Nelson et al., 1999; Pull et al., 1997; Reed et al., 1998; Üstün et al., 1997; 
Wittchen, 1994). The inherent problems of reliability and validity in assessment tools need to 
be acknowledged and the continued need to resolve these critical issues remains of core 
importance for improved future research in this domain.  
 
With these limitations in mind, it should be noted that dependence symptoms are frequent 
among cannabis users: One third of cannabis users aged 17–28 years met criteria for at least 
one dependence symptom in their lifetime, and the number of dependence symptoms 
increased by frequency of use, suggesting some dose-response relationship. It should be 
highlighted that the patterns of dependence symptoms are similar across all use frequency 
groups, irrespective of concomitant use of other illegal and legal drugs as well as frequency of 
use.  
 
Withdrawal was the most frequently reported dependence symptom even among low 
frequency users who did not use other illicit drugs. Other frequent dependence criteria were 
(in decreasing order by frequency): tolerance, loss of control and continued cannabis use 
despite a health problem. Concomitant use of other illicit drugs was not consistently 
associated with increased rates of specific dependence symptoms or their number.  
 
The design features of our study make it difficult to directly compare our findings with the 
small number of previous studies addressing similar questions. However, our range and 
frequency of dependence symptoms are quite similar to those reported in an Australian 
sample of adult cannabis users (over 18 years) studied by Swift and colleagues (Swift et al., 
2001). Participants in this study reported 12-month prevalent DSM-IV dependence symptoms 
as follows: desire to control use (37%), withdrawal (30%), tolerance (22%), loss of control 
(19%), time excess obtaining/recovering (9%), continued use despite health problems (9%) 
and 2% giving-up important activities. According to this, withdrawal and tolerance played a 
similar important role as in our group of high frequency users. Coffey and colleagues (Coffey 
et al., 2002) present 12-month prevalences on a representative sample of young adults (20–21 
years) in Australia, using methods that are similar our study. They show some minor 
differences in symptom ranking compared to our data, and a considerably higher symptom 
occurrence in the Australian sample. These differences may be explained by the fact that the 
Australian data are based on a sample with current (last 12 months) and more frequent (at 
least weekly) cannabis use compared to frequency of use patterns in our sample. Different 
THCcontent in Australian marijuana, differences in dosing and route of administration and 
bio-availability could also explain these higher rates.  
 
The present study adds to the previous findings epidemiological data supporting the validity 
and clinical relevance of the cannabis withdrawal criterion. The high prevalence of 
withdrawal irrespective of the use of other substances supports the concept of a cannabis-
specific syndrome that can “not be explained better by another condition or disorder” (Smith, 
2002, p. 625). The fact that 8% of low frequency users and 46% of high frequency users with 
no illicit drug use report withdrawal, and a further 21% of the HFUs using the substance to 
avoid adverse effects, can be interpreted as signaling a considerable risk for future 
progression into dependence.  
 
To conclude, we could show that a substantial proportion of young cannabis users in the 
general population experience dependence symptoms in their life, including the more 
“physiological” criteria tolerance and withdrawal. Unlike other studies we could rule out the 
influence of other illegal psychoactive substances on the development of dependence by 
separately examining subjects who only used cannabis and subjects with concomitant illegal 
drug use. We could also exclude the possibility that our findings are mediated by comorbid 
nicotine dependence and alcohol dependence. These findings are by and large consistent with 
attempts to develop cannabis-specific preventive and therapeutic programs.  
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